

Resource Summary Report

Generated by T1D on Jul 31, 2026

University of Texas MD Anderson Cancer Center

RRID:SCR_004699

Type: Tool

Proper Citation

University of Texas MD Anderson Cancer Center (RRID:SCR_004699)

Resource Information

URL: <http://www.mdanderson.org/>

Proper Citation: University of Texas MD Anderson Cancer Center (RRID:SCR_004699)

Description: The mission of The University of Texas MD Anderson Cancer Center is to eliminate cancer in Texas, the nation, and the world through outstanding programs that integrate patient care, research and prevention, and through education for undergraduate and graduate students, trainees, professionals, employees and the public. VISION: We shall be the premier cancer center in the world, based on the excellence of our people, our research-driven patient care and our science. We are Making Cancer History.

Abbreviations: MD Anderson Cancer Center

Synonyms: UT M.D. Anderson Cancer Center, M.D. Anderson Cancer Center, UT MD Anderson Cancer Center

Resource Type: institution

Resource Name: University of Texas MD Anderson Cancer Center

Resource ID: SCR_004699

Alternate IDs: Crossref funder ID: 100007313, nif-0000-24365, SCR_008276, nlx_69261, Wikidata: Q1525831, ISNI: 0000 0001 2291 4776, grid.240145.6

Alternate URLs: <https://ror.org/04twxam07>

Record Creation Time: 20220129T080226+0000

Record Last Update: 20260729T044105+0000

Ratings and Alerts

No rating or validation information has been found for University of Texas MD Anderson Cancer Center.

No alerts have been found for University of Texas MD Anderson Cancer Center.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 943 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Moares N, et al. (2025) Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. *Frontiers in immunology*, 16, 1613222.

Hughes SE, et al. (2025) Measure selection for an electronic patient-reported outcome (ePRO) system for CAR T-cell therapy patients: a modified Delphi consensus study. *EClinicalMedicine*, 84, 103256.

Hwang SB, et al. (2025) A Novel Diagnostic Tool for West Nile Virus Lineage 1a and 2 Using a CRISPR-Cas12a System. *Biosensors*, 15(12).

Zheng H, et al. (2025) Identification of prognostic biomarkers associated with T and melanoma cell subpopulations in melanoma through integrating machine learning and multiomics. *Discover oncology*, 16(1), 1742.

Thomson CJ, et al. (2024) Randomized controlled trial investigating the effectiveness of a multimodal mobile application for the treatment of chronic pain. *Canadian journal of pain = Revue canadienne de la douleur*, 8(1), 2352399.

Rafnsdottir S, et al. (2024) SMYD5 is a regulator of the mild hypothermia response. *Cell reports*, 43(8), 114554.

Zhang S, et al. (2023) Lysosomal TMEM9-LAMTOR4-controlled mTOR signaling integrity is required for mammary tumorigenesis. *Cancer communications (London, England)*, 43(1), 159.

Schraml P, et al. (2023) Altered cytoplasmic and nuclear ADP-ribosylation levels analyzed with an improved ADP-ribose binder are a prognostic factor in renal cell carcinoma. *The journal of pathology. Clinical research*, 9(4), 273.

Tu H, et al. (2022) Smoking, smoking cessation, and survival after cancer diagnosis in 128,423 patients across cancer types. *Cancer communications (London, England)*, 42(12), 1421.

Jaiprasart P, et al. (2020) Identification of signature genes associated with therapeutic resistance to anti-VEGF therapy. *Oncotarget*, 11(1), 99.

Hulikal N, et al. (2020) Predicting Response to Neoadjuvant Chemotherapy Using 18F FDG PET-CT in Patients with Locally Advanced Breast Cancer. *Asian Pacific journal of cancer prevention : APJCP*, 21(1), 93.

Zhang X, et al. (2020) Large DNA Methylation Nadirs Anchor Chromatin Loops Maintaining Hematopoietic Stem Cell Identity. *Molecular cell*, 78(3), 506.

Liu W, et al. (2018) Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. *Oncotarget*, 9(1), 346.

Tiwarly S, et al. (2018) Metastatic Brain Tumors Disrupt the Blood-Brain Barrier and Alter Lipid Metabolism by Inhibiting Expression of the Endothelial Cell Fatty Acid Transporter Mfsd2a. *Scientific reports*, 8(1), 8267.

Shen L, et al. (2018) NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis. *Oncogene*, 37(13), 1759.

Pierzynski JA, et al. (2018) Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients. *Scientific reports*, 8(1), 10640.

Jiang B, et al. (2018) Power-law relationship in the long-tailed sections of proton dose distributions. *Scientific reports*, 8(1), 10413.

Khodadadi-Jamayran A, et al. (2018) Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. *Oncotarget*, 9(16), 12868.

Portney BA, et al. (2018) ZSCAN4 is negatively regulated by the ubiquitin-proteasome system and the E3 ubiquitin ligase RNF20. *Biochemical and biophysical research communications*, 498(1), 72.

Gorlova OY, et al. (2018) Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. *PloS one*, 13(1), e0189498.